0.2210 0.00 (0.91%)
After hours: 6:33PM EDT
|Bid||0.2210 x 2900|
|Ask||0.2235 x 1100|
|Day's Range||0.2151 - 0.2235|
|52 Week Range||0.1400 - 2.1800|
|Beta (5Y Monthly)||0.80|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 29, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.50|
In a volatile market, it's more important than ever to hone your technical analysis skills. Here are some near-term trading ideas.
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today reported financial results for the fourth quarter and full year ended December 31, 2019 and provided an update on its business.
NEW YORK, NY / ACCESSWIRE / March 30, 2020 / Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 30, 2020 ...
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that its fourth quarter and full year 2019 financial results will be released after market close on Monday, March 30, 2020.
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) today announced that, since January 1, 2020, it has received proceeds of approximately $5.9 million as a result of the exercise of approximately 26.2 million previously issued Class B common share purchase warrants (the "Class B Warrants").
It is a pleasure to report that the Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) is up 66% in the last quarter. But the...
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) today announced that it has signed an agreement for Probuphine (buprenorphine) implant to be included on the Federal Supply Schedule ("FSS"), providing U.S. veterans and other federal government agencies with access to Titan's novel 6-month maintenance treatment for Opioid Use Disorder ("OUD") in eligible patients. The final FSS contract is effective January 15, 2020 and has a five-year term. The FSS contract will extend access to Probuphine to over nine million VA beneficiaries and others within the federal system.
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced it has entered into a securities purchase agreement with certain accredited institutional investors to purchase approximately $2.2 million of its common stock in a registered direct offering and warrants to purchase shares of common stock in a concurrent private placement. The combined purchase price for one share of common stock and each warrant will be $0.25.
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) today announced that at its recent annual stockholders meeting, Kate DeVarney, Ph.D., its Executive Vice President and Chief Scientific Officer, was elected to the Company's Board of Directors.
In 2015 Sunil Bhonsle was appointed CEO of Titan Pharmaceuticals, Inc. (NASDAQ:TTNP). This report will, first, examine...
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that management will present an update on the Company's business at the first annual BioTuesdays Pre-JPM Virtual Conference on Tuesday, December 10, 2019 at 3:00 p.m. EST / 12:00 p.m. PST.
By John Vandermosten, CFA NASDAQ:TTNP READ THE FULL TTNP RESEARCH REPORT Third Quarter 2019 Financial and Operational Results During the third quarter and to date, Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) has expanded its network to include CVS Caremark, raised additional capital to support its sales and marketing efforts, received approval for additional NIDA funding and presented a pair of
SOUTH SAN FRANCISCO, Calif. , Nov. 14, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today reported financial results for the third quarter ended September 30, 2019 and provided an update ...
SOUTH SAN FRANCISCO, Calif. , Nov. 7, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) will announce its third quarter 2019 financial results after market close on Thursday, November 14, ...
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP) today announced that it has two poster presentations on Probuphine (buprenorphine) implant, Titan's novel 6-month maintenance treatment for Opioid Use Disorder ("OUD") in eligible patients, at the 10th American Conference on Pharmacometrics taking place on October 20-23, 2019 in Orlando, FL. The poster presentations will provide details of the results from computer modeling studies that assessed the population pharmacokinetic ("PK") parameters, exposure-response profiles, and drug-drug interaction ("DDI") potential of the patient plasma levels of buprenorphine during treatment with Probuphine subdermal implants.
While initial public offerings get most of the splash, public companies also are raking in cash with follow-on offerings. How long will the Wall Street spigot stay open?
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP) today announced the pricing of an underwritten public offering of 40,000,000 units at a price to the public of $0.225 per unit. Each unit issued in the offering consists of one share of common stock (or pre-funded warrant in lieu thereof) and one Class B Warrant to purchase one share of common stock. The Class B Warrants will be immediately exercisable at a price of $0.225 per share of common stock and will expire five years from the date of issuance.
SOUTH SAN FRANCISCO, Calif., Oct. 1, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP) and Crossroads of Southern Nevada ("Crossroads") rehabilitation facility today announced that Crossroads has healthcare providers who are specially trained in the insertion and removal of Probuphine® (buprenorphine) implants, and will now offer Probuphine for use in eligible patients with Opioid Use Disorder (OUD). Based in Las Vegas, Crossroads is a drug and alcohol rehabilitation center licensed by the State of Nevada and its Substance Abuse Prevention and Treatment Agency (SAPTA). "We are excited that Crossroads is implementing Probuphine as part of their comprehensive OUD treatment program," said Titan's Executive Vice President and Chief Commercial Officer, Dane Hallberg.
SOUTH SAN FRANCISCO, Calif., Sept. 18, 2019 /PRNewswire/ -- National Institutes of Health's National Institute on Drug Abuse (NIDA) has approved approximately $6.1 million in second-year funding for Titan's non-clinical development of a ProNeura™ based six-month implantable formulation of Nalmefene, an opioid antagonist, intended for the prevention of relapse to opioid addiction, following opioid detoxification. NIDA awarded Titan a two-year grant in the amount of $6.7 million in September 2018 for the project, subject to satisfactory project progress, fund availability and certain other conditions. As a result of a change in the grant award terms regarding company matching funds, the second-year award covers both the Federal and company match amounts of the original year two award, thereby increasing the aggregate potential expense reimbursement to approximately $8.7 million.
Despite several factors in its favor including global expansion and repeat patients, second quarter revenues for Titan Pharmaceuticals, Inc. (TTNP) disappointed and missed our modest growth estimates. Despite an opioid epidemic where almost 70,000 people1 are dying annually, and two million2 are addicted in the United States, sales have languished at around $300,000, despite entering the third year of approval for the ProNeura implant. Titan has taken several steps to advance the commercialization of Probuphine, forging partnerships with AllianceRx to help with payors and fulfillment, with AppianRx to provide patient support and with Accredo for product inventory management, billing and payment as well as deep relationships with third party payors.
Every investor on earth makes bad calls sometimes. But you want to avoid the really big losses like the plague. So...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 15) Novocure Ltd (NASDAQ: NVCR ) Down In The Dumps (Biotech ...